ICI Arthritis Tied to Cancer Progression
MedPage Today reports on the findings of an HSS study published online in ACR Open Rheumatology by rheumatologist Karmela Kim Chan, MD, which suggested cancer patients treated with immune checkpoint inhibitors (ICI) who develop severe arthritis may be at risk for progression of the malignancy.
Dr. Chan and colleagues conducted a multivariable analysis that adjusted for time to onset of arthritis after initiation of ICI therapy and for the use of disease-modifying antirheumatic drugs (DMARDs), each one-point increase in baseline Clinical Disease Activity Index (CDAI) was associated with a 9% increase in the likelihood of cancer progression (HR 1.09, 95% CI 1.00-1.19, P=0.05).
"Untangling the relationship between ICI-arthritis disease severity (e.g., CDAI), ICI-arthritis treatment (e.g., TNF inhibitors), and cancer survival will be critical to the development of safe treatment approaches," the researchers wrote.
Read the full article at Medpagetoday.com.